<DOC>
	<DOCNO>NCT00932880</DOCNO>
	<brief_summary>- Objective : - The objective study compare rate extent absorption test formulation , amlodipine besylate 10 mg tablet ( Torrent Pharmaceuticals Ltd. ) , market reference product , Norvasc® 10 mg tablet ( Pfizer , Inc. ) , administer fed condition . - Study Design : - This open-label , randomize , two-way crossover study 18 healthy subject schedule receive single dose two treatment two assign dose period . Each dose administration separate minimum 14-day washout period .</brief_summary>
	<brief_title>Study Evaluate Bioavailability Test Formulation Amlodipine 10 mg Tablets ( Torrent Pharmaceuticals Limited ) Compared 10 mg Dose Norvasc® ( Pfizer ) 18 Fed , Healthy Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Sex : Male/female . Age : 18 45 year . Volunteer BMI 1827 kg/m2 minimum 50 kg weight . With minimum blood pressure 110/75 mmHg . Healthy willing participate study . Signed Written Informed Consent Screening study . Medical case history , physical examination , vital sign , laboratory test ECG without significant deviation . Negative drug abuse screen test . Nonsmokers smoke less 10 cigarette day willing break smoking course study . No history medication least 2 week prior study drug administration study Period II completion . Clinically relevant abnormal physical finding screen examination , would interfere objective study . Clinically relevant abnormality result laboratory screening evaluation . Abnormal ECG . Habituation tobacco necessitate uninterrupted tobacco consumption . Addiction alcohol history drug abuse . History kidney liver dysfunction . History allergy test drug drug chemically similar drug investigation . Administration/ Intake prescription OTC medication two week study . Patients suffer chronic illness arthritis , asthma etc . HIV , HCV , HBsAg positive volunteer . Opioids cannabis positive volunteer base urine test . Subjects suffer psychiatric ( acute chronic ) illness . Administration investigational drug period 0 3 month entry study . Intake barbiturates enzymeinducing drug last three month . History significant blood loss due reason , include blood donation past 12 week . The total blood loss last 3 month include study exceed 350ml . History bleed disorder . Existence surgical medical condition , , judgement clinical investigator , might interfere absorption , distribution , metabolism excretion drug likely compromise safety volunteer . Serious adverse reaction hypersensitivity study drug excipients . Inability communicate cooperate investigator due language problem , poor mental development impair cerebral function . Pregnant nursing mother . Female practice barrier contraceptive . Contraindications active inactive ingredient formulation . Volunteers leave go holiday . Imminent reassignment job location . Inadequate motivation . Can come followup visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>